U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07133113) titled 'Medium-term Effects of Treatments in Autoimmune Encephalitis' on Aug. 13.
Brief Summary: Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immuno...